Bispecific Antibodies

Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.

Also Known As:

Networked: 383 relevant articles (26 outcomes, 43 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Goldenberg, David M: 12 articles (02/2015 - 05/2002)
2.	Lum, Lawrence G: 10 articles (11/2015 - 01/2004)
3.	Baeuerle, Patrick A: 9 articles (06/2013 - 08/2003)
4.	Lindhofer, Horst: 8 articles (08/2015 - 11/2005)
5.	Asano, Ryutaro: 8 articles (01/2015 - 03/2002)
6.	Ruf, Peter: 6 articles (08/2015 - 09/2008)
7.	Sharkey, Robert M: 6 articles (02/2015 - 05/2002)
8.	Kumagai, Izumi: 6 articles (01/2015 - 03/2002)
9.	Cartellieri, Marc: 6 articles (09/2014 - 06/2011)
10.	Feldmann, Anja: 6 articles (09/2014 - 06/2011)

Related Diseases

1.	Neoplasms (Cancer) 09/01/1997 - "Designed to direct and enhance the body's immune response to specific tumours and pathogens, bispecific antibodies have shown promising results in Phase I and Phase II clinical trials, leading in some cases to complete or partial responses in cancer patients. " 03/01/2014 - "Various constructs of bispecific antibodies (bsAbs) to redirect effector T cells for the targeted killing of tumor cells have shown considerable promise in both preclinical and clinical studies. " 03/01/2015 - "T-cell retargeting bispecific antibodies (BsAb) also have clinical potential, but it is thus far only effective against liquid tumors. " 03/08/2002 - "A number of bispecific antibodies against B-cell markers have been shown to be effective in vitro in mediating tumor cell lysis and in vivo in inhibiting tumor growth in animal models. " 01/01/2011 - "Humanized mice were generated in order to investigate the anti-tumor efficacy of bispecific antibodies. "
2.	Hematologic Neoplasms (Hematological Malignancy) 01/01/2015 - "Bispecific antibodies (bsAbs) engaging T cells are emerging as a promising immunotherapeutic tool for the treatment of hematologic malignancies. " 09/01/2008 - "This review provides a preclinical and clinical perspective on application of bispecific antibodies for the treatment of solid tumors, hematologic malignancies and other diseases. " 01/01/2001 - "Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies." 01/10/2015 - "Recently conducted clinical trials have provided impressive evidence that chemotherapy resistant metastatic melanoma and several hematological malignancies can be cured using adoptive T cell therapy or T cell-recruiting bispecific antibodies. " 11/01/2015 - "Various methods for manipulating the immune system including check-point inhibitors, chimeric antigen receptor T cells, and bispecific antibodies have shown promising activity in treating both hematological malignancies and solid tumors with excellent success. "
3.	Lymphoma (Lymphomas) 10/01/1995 - "In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma." 03/01/2002 - "Bispecific antibodies for lymphoma are also in early clinical testing. " 09/01/2000 - "Bispecific antibodies for lymphoma may also have a future role in lymphoma therapy. " 05/01/2000 - "Alternatively, bispecific antibodies and idiotypic vaccination strategies are used to target autologous T cells to eliminate lymphoma cells. " 12/15/1998 - "These polyclonal CTLs, targeted by the CD3x19 bispecific antibodies, can lyse CD19(+) B-lymphoma cells. "
4.	Hodgkin Disease (Hodgkin's Disease) 04/01/2013 - "Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients." 07/01/2001 - "Treating Hodgkin's disease with bispecific antibodies: Both patients and antibody are limiting." 01/01/2000 - "Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease." 10/01/1998 - "Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease." 01/01/1996 - "Treatment of Hodgkin's disease with bispecific antibodies."
5.	Residual Neoplasm 07/01/2000 - "Bispecific antibodies (bsAb) are considered as promising tools for the elimination of disseminated tumour cells in a minimal residual disease situation. " 06/01/2003 - "Bispecific antibodies (BsAb) with specificity to both tumor cells and CD3 molecule were believed to be promising immunological tools for the therapy with minimal residual diseases by activating cytotoxic T cells. " 10/15/2001 - "Bispecific antibodies (bsAbs) can efficiently mediate tumor cell killing by redirecting preactivated or costimulated T cells to disseminated tumor cells, especially in a minimal residual disease situation. " 07/01/2001 - "Bispecific monoclonal antibodies (bsAbs) are a promising immunotherapeutic option for treatment of cancer, especially in situations of minimal residual disease. " 02/15/2006 - "Trifunctional bispecific antibodies (TbsAbs) capable of cross-linking T lymphocytes, natural killer, and other FcgammaR-positive effector cells, via their Fc region, to the tumor cells may be applied together with adoptive allogeneic-cell therapy to maximize antitumor responses while acting on GVHD in patients with minimal residual disease."

Related Drugs and Biologics

1.	Antibodies
2.	Antigens
3.	Monoclonal Antibodies
4.	Immunoglobulin G (IgG)
5.	T-Cell Antigen Receptors (T-Cell Receptor)
6.	IgG Receptors (Fc gamma RI)
7.	CD30 Antigens
8.	Complement System Proteins (Complement)
9.	Immunotoxins (Immunotoxin)
10.	Antigen Receptors (Antigen Receptor)

Related Therapies and Procedures

1.	Immunotherapy
2.	Therapeutics
3.	Drug Therapy (Chemotherapy)
4.	Tissue Therapy (Cell Therapy)
5.	Heterologous Transplantation (Xenotransplantation)